Department of Health Services Research, Peter MacCallum Cancer Centre, 305 Grattan Street Parkville, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC, 3010, Melbourne, Australia.
BMC Health Serv Res. 2022 Nov 23;22(1):1399. doi: 10.1186/s12913-022-08800-x.
Unmanaged consequences of cancer and its treatment are high among patients with lung cancer and their informal carers, resulting in avoidable healthcare use and financial burden. Provision of cancer supportive care addressing the impacts of cancer and its treatment has demonstrated efficacy in mitigating these consequences; however, globally, there is a lack of investment in these services. Paucity of robust economic evidence regarding benefit of cancer supportive care has limited policy impact and allocation of resources. This study therefore utilised a Social Return on Investment (SROI) methodology to conduct a forecast evaluation of lung cancer supportive care services, to ascertain potential social value and return on investment.
An SROI economic evaluation model was developed using qualitative stakeholder consultations synthesised with published evidence to develop the inputs, outcomes and financial value associated with the delivery of a hypothetical model of quality lung cancer supportive care services over a one and five year period. SROI ratios were generated to determine the social value and cost savings associated per every $1AUD invested in cancer supportive care for both the healthcare system and patients. Deadweight, drop off and attribution were calculated, and sensitivity analysis was performed to confirm the stability of the model.
The value generated from modelled supportive care service investments in a one-year period resulted in an SROI ratio of 1:9; that is, for every dollar invested in supportive care, AUD$9.00 social return is obtained when savings to the healthcare system and benefits to the patients are combined. At five-years, these same investments resulted in greater cumulative value generated for both the patient and the healthcare system, with a SROI ratio of 1:11.
Our study provides strong evidence for policy makers, clinicians and consumers to advocate for further investment in cancer supportive care, as demonstrated cost savings could be achieved through implementation of the proposed supportive care service model, with these accruing over a five-year period. The SROI model provides a comprehensive framework detailing supportive care services and the health workforce necessary to achieve value-based outcomes for patients and the healthcare system.
肺癌患者及其非正式照顾者的癌症及其治疗带来的管理不善后果很高,导致不必要的医疗保健利用和经济负担。提供癌症支持性护理以应对癌症及其治疗的影响已被证明能减轻这些后果;然而,在全球范围内,对这些服务的投资不足。关于癌症支持性护理效益的强有力经济证据的缺乏限制了政策的影响和资源的分配。因此,本研究利用社会投资回报率(SROI)方法对肺癌支持性护理服务进行预测性评估,以确定潜在的社会价值和投资回报。
使用定性利益相关者咨询意见合成发表的证据,开发了一种 SROI 经济评估模型,以开发与提供假设的优质肺癌支持性护理服务模型相关的投入、结果和财务价值,为期一年和五年。生成 SROI 比率,以确定每投资 1 澳元用于癌症支持性护理时,医疗保健系统和患者的社会价值和成本节约。计算了死重、下降和归因,并进行了敏感性分析以确认模型的稳定性。
在一年的时间内,对支持性护理服务投资产生的价值产生了 1:9 的 SROI 比率;也就是说,每投资 1 澳元用于支持性护理,当结合医疗保健系统的节省和患者的收益时,可获得 9.00 澳元的社会回报。在五年内,患者和医疗保健系统都产生了更大的累积价值,SROI 比率为 1:11。
我们的研究为政策制定者、临床医生和消费者提供了强有力的证据,以倡导进一步投资于癌症支持性护理,因为实施拟议的支持性护理服务模型可以实现成本节约,这些节约将在五年内累积。SROI 模型提供了一个全面的框架,详细说明了支持性护理服务和卫生劳动力,以实现患者和医疗保健系统的基于价值的结果。